Valion Bio Advances Entolimod to Therapeutic Study
The Armed Forces Radiobiology Research Institute will test Entolimod's therapeutic efficacy in a radiation-exposure mouse model funded by NIAID.
Updated on Nov. 2, 2026 in Biotech
Valion Bio, a clinical-stage biopharmaceutical company, is advancing its drug Entolimod into a therapeutic efficacy evaluation at the Armed Forces Radiobiology Research Institute. The study is fully funded by NIAID's Radiation and Nuclear Countermeasures Program under an Interagency Agreement with the Uniformed Services University.
Why it matters
Entolimod is being developed as a potential medical countermeasure for acute radiation syndrome. The move to the therapeutic phase followed days after Valion announced positive safety results for the drug.
The study uses a partial-body irradiation model shielding about 2.5% of bone marrow, with a single Entolimod or saline dose given 24 hours after radiation and survival tracked over 30 days. Whether Entolimod improves survival over the control group remains untested until results arrive.
The players
Valion Bio
Valion Bio is a clinical-stage biopharmaceutical company developing Entolimod as a potential countermeasure for acute radiation syndrome.
Armed Forces Radiobiology Research Institute
The Armed Forces Radiobiology Research Institute is a U.S. military research facility that conducts radiobiology studies, including radiation countermeasure evaluations.
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases is a component of the National Institutes of Health that funds research on infectious and immune-related diseases, including its Radiation and Nuclear Countermeasures Program.
The details
Mice will receive either Entolimod or a saline control 24 hours after radiation exposure, with the primary endpoint being survival compared between the two groups. The therapeutic study is conducted at the Armed Forces Radiobiology Research Institute.
Timeline
November 2, 2026: Valion announces the AFRRI therapeutic efficacy evaluation.
Early December 2026: Top-line results of the therapeutic study are anticipated.
Roadmap
Federal funding through NIAID's Radiation and Nuclear Countermeasures Program supports the U.S. effort to develop treatments for acute radiation syndrome. Entolimod's advance into efficacy testing places it among the candidates being evaluated under that federal program.
For most Americans this development is a research milestone rather than an immediate change in care, since the drug has not yet demonstrated efficacy. Any eventual approval would affect emergency preparedness for acute radiation syndrome rather than routine treatment.
The takeaway
Advancing a drug from safety to efficacy testing is a necessary step, but it does not yet show that the treatment works. Readers should watch for the December top-line results before drawing conclusions about Entolimod's potential.
What happens next
Top-line results from the therapeutic efficacy study are anticipated in early December 2026.
Further reading
Explore more Biotech coverage for context on drug development pipelines like this one.
